Groepsleider: Dr. Lieve Tytgat
Phone 088 97 29 530
"Translationeel onderzoek: waar het onderzoek en de zorg elkaar ontmoeten." Dr. Lieve Tytgat - Groepsleider
Belangrijke publicaties
Stutterheim J., Gerritsen A., Zappeij-Kannegieter L., Kleijn I., Dee R., Hooft L., van Noesel M., Bierings M., BertholdF., Versteeg R., Caron H.N., van der Schoot C.e., Tytgat G.A. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. (2008) J Clin Oncol. 26:5443-9. PubMed PMID: 18838715
Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA, van der Schoot CE. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. (2012) Clin Cancer Res. 18:808-14. PubMed PMID: 22142825
Bleeker G, van Eck-Smit BL, Zwinderman KH, Versteeg R, van Noesel MM, Kam BL, Kaspers GJ, van Schie A, Kreissman SG, Yanik G, Hero B, Schmidt M, Laureys G, Lambert B, Ora I, Schulte JH, Caron HN, Tytgat GA. MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. (2014) Eur J Nucl Med Mol Imaging. 42:222-30. PubMed PMID: 25267348
van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, Versteeg R, Fiocco M, Caron HN, van der Schoot CE, Koster J, Tytgat GA. Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. (2015) J Mol Diagn. 17:43-52. PubMed PMID: 25445214
Verly IRN, van Kuilenburg ABP, Abeling NGGM, Goorden SMI, Fiocco M, Vaz FM, van Noesel MM, Zwaan CM, Kaspers GJL, Merks JHM, Caron HN, Tytgat GAM. 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. (2018) Eur J Cancer. b102-110. PubMed PMID: 29274926
Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA, van der Schoot CE. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. (2012) Clin Cancer Res. 18:808-14. PubMed PMID: 22142825
Bleeker G, van Eck-Smit BL, Zwinderman KH, Versteeg R, van Noesel MM, Kam BL, Kaspers GJ, van Schie A, Kreissman SG, Yanik G, Hero B, Schmidt M, Laureys G, Lambert B, Ora I, Schulte JH, Caron HN, Tytgat GA. MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. (2014) Eur J Nucl Med Mol Imaging. 42:222-30. PubMed PMID: 25267348
van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, Versteeg R, Fiocco M, Caron HN, van der Schoot CE, Koster J, Tytgat GA. Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. (2015) J Mol Diagn. 17:43-52. PubMed PMID: 25445214
Verly IRN, van Kuilenburg ABP, Abeling NGGM, Goorden SMI, Fiocco M, Vaz FM, van Noesel MM, Zwaan CM, Kaspers GJL, Merks JHM, Caron HN, Tytgat GAM. 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. (2018) Eur J Cancer. b102-110. PubMed PMID: 29274926
